Synthesis of novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure-activity relationships for non-sulfhydryl and sulfhydryl types

Citations Over TimeTop 12% of 1986 papers

Abstract

The synthesis and angiotensin converting enzyme (ACE) inhibiting activities of quinapril (CI-906, 22), its active diacid (CI-928, 33), and its dimethoxy analogue (CI-925, 25) are reported. These tetrahydro-3-isoquinolinecarboxylic acid derivatives possess equivalent in vitro potency and in vivo efficacy to enalapril. Sulfhydryl analogues with the same structural variation are also highly potent. In contrast, tetrahydro-1-isoquinolinecarboxylic acid and homologous isoindoline-1-carboxylic acid analogues show a striking divergence in potency between the two types, sulfhydryl analogues being essentially inactive, while non-sulfhydryl analogues are equipotent with the proline prototype. This is the first evidence suggesting that alternate binding modes may exist for the two major structural classes of small molecule ACE inhibitors.

Related Papers

• Exploring the effects of ACE inhibitor tissue penetration on vascular inflammation following acute myocardial infarction.(2004)
• → Heart Rate Variability in Conscious and Anesthetized Rats under the Action of Angiotensin Converting Enzyme Inhibitors(2012)5 cited
• Quinapril versus lisinopril in the treatment of essential hypertension in elderly patients with low blood renin.(1996)
• → Thin-layer chromatography of several antihypertensive drugs from the group of angiotensin converting enzyme inhibitors(2001)9 cited
• [A comparative study of the effects of lisinopril and quinapril administered once a day in essential hypertension].(1990)